{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T21:51:57Z","timestamp":1791409917619,"version":"4.3.3"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic Chemistry"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.bioorg.2026.110362","type":"journal-article","created":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T00:34:01Z","timestamp":1786322041000},"page":"110362","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Design, synthesis, biological evaluation, and mechanistic characterization of novel dual VEGFR2\/CRAF-directed kinase inhibitors with potent antitumor activity"],"prefix":"10.1016","volume":"181","author":[{"given":"Yida","family":"Yu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yihao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rongjian","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"45","key":"10.1016\/j.bioorg.2026.110362_bb0005","doi-asserted-by":"crossref","first-page":"33384","DOI":"10.1039\/D4RA05244G","article-title":"Recent updates on potential of VEGFR-2 small-molecule inhibitors as anticancer agents","volume":"14","author":"Chaudhari","year":"2024","journal-title":"RSC Adv."},{"issue":"9","key":"10.1016\/j.bioorg.2026.110362_bb0010","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/1061186X.2025.2508985","article-title":"Revisiting VEGF\/VEGFR-2 signalling as an anticancer target and its inhibitor discovery: where are we and where should we go?","volume":"33","author":"Yao","year":"2025","journal-title":"J. Drug Target."},{"issue":"1","key":"10.1016\/j.bioorg.2026.110362_bb0015","first-page":"50","article-title":"Tumor angiogenesis and VEGFR-2: mechanism, pathways and current biological therapeutic interventions","volume":"22","author":"Shah","year":"2021","journal-title":"Curr. Drug Metab."},{"key":"10.1016\/j.bioorg.2026.110362_bb0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2023.106425","article-title":"Recent development of multi-target VEGFR-2 inhibitors for the cancer therapy","volume":"133","author":"Liu","year":"2023","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2026.110362_bb0025","doi-asserted-by":"crossref","first-page":"1307860","DOI":"10.3389\/fphar.2023.1307860","article-title":"Recent advances of anti-angiogenic inhibitors targeting VEGF\/VEGFR axis","volume":"14","author":"Wang","year":"2024","journal-title":"Front. Pharmacol."},{"issue":"1","key":"10.1016\/j.bioorg.2026.110362_bb0030","doi-asserted-by":"crossref","DOI":"10.1002\/jmr.3104","article-title":"Computer-aided design of VEGFR-2 inhibitors as anticancer agents: a review","volume":"38","author":"Uba","year":"2025","journal-title":"J. Mol. Recognit."},{"issue":"5","key":"10.1016\/j.bioorg.2026.110362_bb0035","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1167\/iovs.64.5.28","article-title":"Mechanisms of acquired resistance to anti-VEGF therapy for neovascular eye diseases","volume":"64","author":"Sharma","year":"2023","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"issue":"5","key":"10.1016\/j.bioorg.2026.110362_bb0040","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1007\/s12272-025-01545-1","article-title":"Targeting vascular endothelial growth receptor-2 (VEGFR-2): structural biology, functional insights, and therapeutic resistance","volume":"48","author":"Shah","year":"2025","journal-title":"Arch. Pharm. Res."},{"key":"10.1016\/j.bioorg.2026.110362_bb0045","article-title":"Molecular bases of VEGFR-2-mediated physiological function and pathological role","volume":"8","author":"Wang","year":"2020","journal-title":"Front. Cell Dev. Biol."},{"issue":"4","key":"10.1016\/j.bioorg.2026.110362_bb0050","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1007\/s12079-016-0352-8","article-title":"VEGF-A\/VEGFR2 signaling network in endothelial cells relevant to angiogenesis","volume":"10","author":"Abhinand","year":"2016","journal-title":"Journal of Cell Communication and Signaling"},{"issue":"1","key":"10.1016\/j.bioorg.2026.110362_bb0055","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1186\/s12876-018-0870-3","article-title":"Apatinib affect VEGF-mediated cell proliferation, migration, invasion via blocking VEGFR2\/RAF\/MEK\/ERK and PI3K\/AKT pathways in cholangiocarcinoma cell","volume":"18","author":"Huang","year":"2018","journal-title":"BMC Gastroenterol."},{"issue":"1","key":"10.1016\/j.bioorg.2026.110362_bb0060","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/s12013-013-9781-7","article-title":"VEGFR, RET, and RAF\/MEK\/ERK pathway take part in the inhibition of osteosarcoma MG63 cells with sorafenib treatment","volume":"69","author":"Mei","year":"2014","journal-title":"Cell Biochem. Biophys."},{"issue":"2","key":"10.1016\/j.bioorg.2026.110362_bb0065","doi-asserted-by":"crossref","DOI":"10.3390\/cancers16020350","article-title":"Exploring the spectrum of VEGF inhibitors\u2019 toxicities from systemic to intra-vitreal usage in medical practice","volume":"16","author":"Santorsola","year":"2024","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10.1016\/j.bioorg.2026.110362_bb0070","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/s00204-024-03874-4","article-title":"Hypertension toxicity of VEGFR-TKIs in cancer treatment: incidence, mechanisms, and management strategies","volume":"99","author":"Du","year":"2025","journal-title":"Arch. Toxicol."},{"issue":"1","key":"10.1016\/j.bioorg.2026.110362_bb0075","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1186\/s13045-022-01310-7","article-title":"Recent progress on vascular endothelial growth factor receptor inhibitors with dual targeting capabilities for tumor therapy","volume":"15","author":"Liu","year":"2022","journal-title":"J. Hematol. Oncol."},{"issue":"12","key":"10.1016\/j.bioorg.2026.110362_bb0080","doi-asserted-by":"crossref","first-page":"9776","DOI":"10.1021\/acs.jmedchem.3c01629","article-title":"Overcoming secondary mutations of type II kinase inhibitors","volume":"67","author":"Wang","year":"2024","journal-title":"J. Med. Chem."},{"issue":"7","key":"10.1016\/j.bioorg.2026.110362_bb0085","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1038\/nchembio799","article-title":"Rational design of inhibitors that bind to inactive kinase conformations","volume":"2","author":"Liu","year":"2006","journal-title":"Nat. Chem. Biol."},{"issue":"20","key":"10.1016\/j.bioorg.2026.110362_bb0090","doi-asserted-by":"crossref","first-page":"20859","DOI":"10.1021\/acs.jmedchem.5c00287","article-title":"Challenges of Aufheben to promote Druglikeness: chemical modification strategies to improve aqueous solubility and permeability","volume":"68","author":"Ishikawa","year":"2025","journal-title":"J. Med. Chem."},{"issue":"43","key":"10.1016\/j.bioorg.2026.110362_bb0095","doi-asserted-by":"crossref","first-page":"36441","DOI":"10.1039\/D5RA05472A","article-title":"Medicinal chemistry perspectives on anticancer drug design based on clinical applications (2015\u20132025)","volume":"15","author":"Al-Karmalawy","year":"2025","journal-title":"RSC Adv."},{"issue":"10","key":"10.1016\/j.bioorg.2026.110362_bb0100","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1007\/s11094-023-02790-8","article-title":"Pharmacological strategies for overcoming multidrug resistance to chemotherapy","volume":"56","author":"Fedotcheva","year":"2023","journal-title":"Pharm. Chem. J."},{"issue":"1","key":"10.1016\/j.bioorg.2026.110362_bb0105","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1515\/oncologie-2023-0459","article-title":"The tumor microenvironment: a key player in multidrug resistance in cancer","volume":"26","author":"Meng","year":"2024","journal-title":"Oncologie"},{"issue":"5","key":"10.1016\/j.bioorg.2026.110362_bb0110","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/j.ejps.2012.03.012","article-title":"Inhibition of P-glycoprotein functionality by vandetanib may reverse cancer cell resistance to doxorubicin","volume":"46","author":"Jovelet","year":"2012","journal-title":"Eur. J. Pharm. Sci."},{"issue":"5","key":"10.1016\/j.bioorg.2026.110362_bb0115","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1245\/s10434-009-0395-7","article-title":"MDR1\/P-gp and VEGF synergistically enhance the invasion of Hep-2 cells with multidrug resistance induced by taxol","volume":"16","author":"Li","year":"2009","journal-title":"Ann. Surg. Oncol."},{"key":"10.1016\/j.bioorg.2026.110362_bb0120","article-title":"Anlotinib reverses multidrug resistance (MDR) in osteosarcoma by inhibiting P-glycoprotein (PGP1) function in vitro and in vivo","volume":"12","author":"Wang","year":"2022","journal-title":"Front. Pharmacol."},{"issue":"6","key":"10.1016\/j.bioorg.2026.110362_bb0125","doi-asserted-by":"crossref","first-page":"897","DOI":"10.3390\/life12060897","article-title":"Multidrug resistance of cancer cells and the vital role of P-glycoprotein","volume":"12","author":"Karthika","year":"2022","journal-title":"Life"},{"issue":"23","key":"10.1016\/j.bioorg.2026.110362_bb0130","doi-asserted-by":"crossref","DOI":"10.3390\/ijms262311448","article-title":"Targeting the MEK\/ERK pathway to suppress P-glycoprotein and reverse carfilzomib resistance in multiple myeloma","volume":"26","author":"Laletina","year":"2025","journal-title":"Int. J. Mol. Sci."},{"issue":"5","key":"10.1016\/j.bioorg.2026.110362_bb0135","doi-asserted-by":"crossref","first-page":"119","DOI":"10.3892\/ijo.2023.5567","article-title":"Mechanism of multidrug resistance to chemotherapy mediated by P-glycoprotein","volume":"63","author":"Tian","year":"2023","journal-title":"Int. J. Oncol."},{"issue":"4","key":"10.1016\/j.bioorg.2026.110362_bb0140","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1002\/ddr.21918","article-title":"Approaches to minimize the effects of P-glycoprotein in drug transport: a review","volume":"83","author":"Husain","year":"2022","journal-title":"Drug Dev. Res."},{"issue":"31","key":"10.1016\/j.bioorg.2026.110362_bb0145","doi-asserted-by":"crossref","first-page":"2535","DOI":"10.2174\/1568026623666221025111528","article-title":"The tetrahydroisoquinoline scaffold in ABC transporter inhibitors that act as multidrug resistance (MDR) reversers","volume":"22","author":"Teodori","year":"2022","journal-title":"Curr. Top. Med. Chem."},{"issue":"11","key":"10.1016\/j.bioorg.2026.110362_bb0150","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1038\/s41568-023-00612-3","article-title":"Advances in the structure, mechanism and targeting of chemoresistance-linked ABC transporters","volume":"23","author":"Sajid","year":"2023","journal-title":"Nat. Rev. Cancer"},{"issue":"10","key":"10.1016\/j.bioorg.2026.110362_bb0155","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1002\/bkcs.12721","article-title":"Discovery of dual inhibitors of pan-RAF and VEGFR2","volume":"44","author":"Park","year":"2023","journal-title":"Bull. Korean Chem. Soc."},{"issue":"10","key":"10.1016\/j.bioorg.2026.110362_bb0160","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.3390\/cells10102509","article-title":"ERK: a double-edged sword in cancer. ERK-dependent apoptosis as a potential therapeutic strategy for cancer","volume":"10","author":"Sugiura","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.bioorg.2026.110362_bb0165","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2026.1760947","article-title":"The cGAS\u2013STING pathway in cancer immunotherapy: prognostic value and therapeutic potential","volume":"17","author":"Alabi","year":"2026","journal-title":"Front. Immunol."},{"issue":"16","key":"10.1016\/j.bioorg.2026.110362_bb0170","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15164127","article-title":"Conventional DNA-damaging cancer therapies and emerging cGAS-STING activation: a review and perspectives regarding immunotherapeutic potential","volume":"15","author":"Lewicky","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"2","key":"10.1016\/j.bioorg.2026.110362_bb0175","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1007\/s11696-018-0587-3","article-title":"Synthesis and biological evaluation of 2, 4-disubstituted thiazole amide derivatives as anticancer agent","volume":"73","author":"Zhang","year":"2019","journal-title":"Chem. Pap."}],"container-title":["Bioorganic Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206826008989?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206826008989?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T21:16:13Z","timestamp":1791407773000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0045206826008989"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":35,"alternative-id":["S0045206826008989"],"URL":"https:\/\/doi.org\/10.1016\/j.bioorg.2026.110362","relation":{},"ISSN":["0045-2068"],"issn-type":[{"value":"0045-2068","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Design, synthesis, biological evaluation, and mechanistic characterization of novel dual VEGFR2\/CRAF-directed kinase inhibitors with potent antitumor activity","name":"articletitle","label":"Article Title"},{"value":"Bioorganic Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bioorg.2026.110362","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"110362"}}